Ethylenediaminetetraacetic acid-dependent pseudothrombocytopenia in a patient with systemic lupus erythematosus and lupus nephritis

Akyol, Lütfi; Önem, Soner; Özgen, Metin; Sayarlıoğlu, Mehmet

doi:10.5152/eurjrheum.2015.0115

Cited by 1 publication

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As the in vitro phenomenon of PTCP could be misdiagnosed with thrombocytopenia, it does affect diagnostic, management, and therapeutic decisions. Inadequate treatments such as platelet transfusion [ 2 , 80 , 128 , 130 , 135 ] or high doses corticosteroids against immune thrombocytopenia [ 49 , 83 , 100 ] may be frequently used, hopefully with minor iatrogenic consequences. Nonetheless, other implications such as discontinuation of heparin therapy could be potentially life-threatening [ 81 ].…”

Section: Discussionmentioning

confidence: 99%

Pseudothrombocytopenia—A Review on Causes, Occurrence and Clinical Implications

Lardinois

Favresse

Châtelain

et al. 2021

JCM

View full text Add to dashboard Cite

Pseudothrombocytopenia (PTCP), a relative common finding in clinical laboratories, can lead to diagnostic errors, overtreatment, and further (even invasive) unnecessary testing. Clinical consequences with potential life-threatening events (e.g., unnecessary platelet transfusion, inappropriate treatment including splenectomy or corticosteroids) are still observed when PTCP is not readily detected. The phenomenon is even more complex when occurring with different anticoagulants. In this review we present a case of multi-anticoagulant PTCP, where we studied different parameters including temperature, amikacin supplementation, measurement methods, and type of anticoagulant. Prevalence, clinical risk factors, pre-analytical and analytical factors, along with clinical implications, will be discussed. The detection of an anticoagulant-dependent PTCP does not necessarily imply the presence of specific disorders. Conversely, the incidence of PTCP seems higher in patients receiving low molecular weight heparin, during hospitalization, or in men aged 50 years or older. New analytical technologies, such as fluorescence or optical platelet counting, will be soon overturning traditional algorithms and represent valuable diagnostic aids. A practical laboratory approach, based on current knowledge of PTCP, is finally proposed for overcoming spuriously low platelet counts.

show abstract